Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil inPIK3CAmutant gastric cancer cells

Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer

(2011) Wen Lee Tan et al.   CANCER BIOLOGY & THERAPY

Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma

(2011) Sandrine Guillard et al.   CELL CYCLE

Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells

(2010) Xinxin Bu et al.   CANCER BIOLOGY & THERAPY

RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase

(2010) Kyung-Hun Lee et al.   CANCER LETTERS

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic

(2010) P. Workman et al.   CANCER RESEARCH

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer

(2009) Taro Matsuzaki et al.   CANCER SCIENCE

Gastric cancer in the era of molecularly targeted agents: current drug development strategies

(2009) Hendrik-Tobias Arkenau   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair

(2009) M -A Westhoff et al.   ONCOGENE

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition

(2008) Neil E. Torbett et al.   BIOCHEMICAL JOURNAL

Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy

(2008) P.H. Clingen et al.   BIOCHEMICAL PHARMACOLOGY

Live or Let Die: E2F1 and PI3K Pathways Intersect to Make Life or Death Decisions

(2008) Brian David Dynlacht   CANCER CELL

Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity

(2008) R. Prevo et al.   CANCER RESEARCH

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

(2008) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY